Top Qs
Timeline
Chat
Perspective
Nivolumab/relatlimab
Combination drug From Wikipedia, the free encyclopedia
Remove ads
Nivolumab/relatlimab, sold under the brand name Opdualag, is a fixed-dose combination medication use to treat melanoma.[10] It contains nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody.[10] It is given by intravenous infusion.[10]
The combination was approved for medical use in the United States in March 2022,[10][12] and in the European Union in September 2022.[11] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[13][14]
Remove ads
Medical uses
The combination is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in people aged twelve years of age and older.[10][11]
Society and culture
Legal status
In July 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Opdualag, intended for the treatment of melanoma.[11][15] The applicant for this medicinal product is Bristol-Myers Squibb Pharma EEIG.[15] Opdualag was approved for medical use in the European Union in September 2022.[11][16]
In January 2024, the National Institute for Health and Care Excellence (NICE) recommended nivolumab-relatlimab[17] as a first-line treatment of advanced melanoma in patients aged 12 years and older.[18]
Remove ads
References
Further reading
External links
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads